Nantahala Capital Management LLC Purchases New Position in TriSalus Life Sciences, Inc. $TLSI

Nantahala Capital Management LLC acquired a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,000,000 shares of the company’s stock, valued at approximately $4,550,000. Nantahala Capital Management LLC owned about 1.62% of TriSalus Life Sciences at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Light Asset Management LLC bought a new stake in shares of TriSalus Life Sciences during the first quarter valued at about $20,267,000. Perkins Capital Management Inc. bought a new position in shares of TriSalus Life Sciences in the first quarter valued at approximately $920,000. Wasatch Advisors LP purchased a new position in TriSalus Life Sciences during the first quarter valued at approximately $5,752,000. Empire Financial Management Company LLC grew its stake in TriSalus Life Sciences by 316.9% during the first quarter. Empire Financial Management Company LLC now owns 300,275 shares of the company’s stock valued at $1,201,000 after acquiring an additional 228,248 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in TriSalus Life Sciences by 35.5% during the 4th quarter. Geode Capital Management LLC now owns 751,207 shares of the company’s stock worth $5,245,000 after acquiring an additional 196,752 shares during the period. 2.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TLSI has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Friday, August 7th. Lake Street Capital reduced their price target on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Finally, Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, TriSalus Life Sciences has an average rating of “Hold” and a consensus price target of $7.50.

TriSalus Life Sciences Trading Down 2.0%

Shares of TriSalus Life Sciences stock opened at $4.83 on Friday. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97. TriSalus Life Sciences, Inc. has a 1 year low of $2.20 and a 1 year high of $7.95. The firm has a market cap of $297.43 million, a PE ratio of -3.72 and a beta of 0.43. The company has a 50 day simple moving average of $4.66 and a two-hundred day simple moving average of $4.32.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). The firm had revenue of $11.41 million for the quarter, compared to analysts’ expectations of $10.27 million.

TriSalus Life Sciences Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.